电子输送链和mTOR抑制协同降低CD40信号传递,并抵消慢性淋巴细胞白血病中的venetoclax抵抗
Zhenghao Chen1, Gaspard Cretenet1, Valeria Carnazzo2
1Experimental Immunology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands; Hematology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands; Amsterdam Institute for Infection and Immunity, Cancer Immunology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Cancer Immunology, Amsterdam, The Netherlands; Lymphoma and Myeloma Center, Amsterdam.
CD40刺激促进慢性淋巴细胞白血病 (CLL) 细胞的代谢变化,导致对venetoclax的抵抗. 抑制电子传输链和mTOR通路可以克服这种阻力,提供潜在的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症新陈代谢 癌症新陈代谢
背景情况:
- 慢性淋巴细胞白血病 (CLL) 中的CD40信号升级调节BCL-XL和MCL-1,从而产生对venetoclax的抗性.
- 威尼托克拉克斯耐药性与代谢变化有关,但机制尚不清楚.
- CD40刺激作为瘤微环境诱导的代谢变化影响药物敏感性的模型.
研究的目的:
- 研究CD40刺激诱导的代谢变化如何影响CLL中的venetoclax敏感性.
- 为了确定参与CD40介导的venetoclax耐药性的特定代谢途径.
主要方法:
- 激发CLL细胞的CD40刺激.
- 评估代谢途径,包括氧化酸化和糖解.
- 抑制线粒体进口,电子运输链 (ETC) 复合体和mTOR信号传递.
- 对BCL-XL,MCL-1表达和细胞信号的评估.
主要成果:
- CD40刺激增加了氧化酸化和糖解;只有氧化酸化抑制可以抵消venetoclax耐药性.
- 抑制ETC复合体 (I,III,V) 降低了CLL激活,ATP产生,降低了MCL-1/BCL-XL的调控,与CD40表达的减少相关.
- 结合ETC和mTOR抑制协同克服了与控制一般蛋白质翻译相关的venetoclax耐药性.
结论:
- 在CLL中,氧化代谢与CD40表达和细胞信号传递有关.
- 针对电子传输链和mTOR通路提供了一种潜在的策略,以克服CLL中的venetoclax电阻.
- 这些发现表明组合疗法的潜在临床应用.
更多相关视频
10:49A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers
Published on: September 26, 2019
08:49Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Inhibition of Cdk Activity
The Intrinsic Apoptotic Pathway
